Impact of nanopore platform on rapid diagnosis of COVID-19 in patients with respiratory tract infections

Impact of nanopore platform on rapid diagnosis of COVID-19 in patients with respiratory tract infections - Impact of nanopore platform on rapid diagnosis of COVID-19 in patients with respiratory tract infections

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042723

Enrollment

500

Registered

2020-12-11

Start date

2020-12-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with suspected COVID-19 or diagnosed as COVID-19

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with suspected COVID-19 or diagnosed as COVID-19

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
Diagnostic accuracy of the nanopore testing for COVID-19 in patients with suspected COVID-19	—

Secondary

Measure	Time frame
Comparison of changes in antibody titers over time and clinical outcomes	—

Countries

Japan

Contacts

Public ContactJumpei Yoshimura

Osaka University Graduate School of Medicine Department of Traumatology and Acute Critical Medicine

jumpei.y0210@gmail.com06-6879-5111

Outcome results